Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Thoracic 1Sarcoma 1Myeloid 1Lymphoid 1

Conditions

Sarcoma, Myeloid 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 55Specimen Handling 50Magnetic Resonance Spectroscopy 49Doxorubicin 44pembrolizumab 43Radiotherapy 42Temozolomide 38Biopsy 34Radiation 29Nivolumab 28fludarabine 23Vincristine 22Irinotecan 21Gemcitabine 21X-Rays 20Ifosfamide 20Surgical Procedures, Operative 19atezolizumab 17cabozantinib 15Ipilimumab 15olaparib 13Sunitinib 13Paclitaxel 13Etoposide 13Blood Specimen Collection 13regorafenib 12fludarabine phosphate 12Phantoms, Imaging 12Imatinib Mesylate 12liposomal doxorubicin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leyk × Sarcoma × 1 year × Clear all
NCT01371981 2026-06-02

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
1,645 enrolled 32 charts
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡